Fulcrum Therapeutics Inc (FULC)
3.265
+0.06
(+1.71%)
USD |
NASDAQ |
Nov 04, 16:00
3.265
0.00 (0.00%)
After-Hours: 16:47
Fulcrum Therapeutics Research and Development Expense (Annual): 71.80M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 71.80M |
| December 31, 2022 | 76.78M |
| December 31, 2021 | 69.70M |
| December 31, 2020 | 59.04M |
| Date | Value |
|---|---|
| December 31, 2019 | 71.07M |
| December 31, 2018 | 25.18M |
| December 31, 2017 | 18.49M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
59.04M
Minimum
2020
76.78M
Maximum
2022
69.68M
Average
71.07M
Median
2019
Research and Development Expense (Annual) Benchmarks
| Bioventus Inc | 13.45M |
| Arcturus Therapeutics Holdings Inc | 192.13M |
| Entrada Therapeutics Inc | 99.88M |
| Johnson & Johnson | 15.08B |
| Insmed Inc | 571.01M |